Skip to content
Home » COVID-19 (Coronavirus) Vaccine Status

COVID-19 (Coronavirus) Vaccine Status

Coronavirus Vaccine Status Of 7 Leading Companies

COVID-19 Vaccine
COVID-19 Vaccine
Source : financialexpress

More than 100 potential COVID-19 Vaccines are in various stages of development around the World. However, Robin Shattock, an Imperial College London professor said that early vaccines may come with some limitations on what they can deliver.

AstraZeneca, Pfizer, BioNtech, Johnson & Johnson, Merck, Moderna, Sanofi and China CanSino Biologics are top runners in human trial stage currently.

?BIOCAD Biotechnology COVID-19 Vaccine

BIOCAD is the Russian Biotechnology Company COVID-19
BIOCAD is the Russian Biotechnology Company
Source : tadviser

This company have a scientists collaboration with Novosibirsk Vector currently working on its own development of the mRNA vaccine against coronavirus (SARS-CoV-2). Developments on COVID-19 will be carried out on the basis of previous developments in cancer vaccines.

This vaccine development process reached the final animal safety study stage. According to the scientists, vaccine show good results in tests on laboratory animals including lower primates.

?Morderna COVID-19 Vaccine

The headquarters of Moderna Therapeutics
The headquarters of Moderna Therapeutics
Source : womansera

In latest evolution, Moderna Inc said that a series of studies on a group of mouses mRNA-1273, has finalised the phase 3 study protocol which will include approximately 30,000 participants. The random, placebo controlled trial is expected to begin in July. Vaccine give some promises that it may not increase the risk of serious disease. The vaccine is being jointly developed by the US National Institutes of Health.

“If company sustain the momentum to be able to deliver approx. 500 million doses per year, and possibly upto 1 billion doses per year, beginning in 2021 from the company internal US manufacturing site and strategic collaboration with Lonza” the company said that in a press release

This vaccine also appeared to protect against the infection by coronavirus in lungs and noses without any evidence of toxic effects, the team wrote.

Scientists also noted the group of mouse who received just one dose before virus given to them, seven weeks later, they were “completely protected against lung viral duplication,” suggesting a single vaccination prevented the virus from duplicating in lungs.

On 6 May 2020, the US Food and Drug Administration completed their review of the company investigational new drug application for mRNA-1273 vaccine and on 11 May 2020, FDA grant permission for their fast track designation.

On 18 May 2020, Moderna announced data from the Phase 1 study of mRNA-1273 led by National Institute of Allergy and Infectious Diseases (NIAID). As per Moderna released early-stage data on small group of healthy volunteers showed successfully produced protective antibodies.

?Sinovac Biotech COVID-19 Vaccine

Chinese firm Sinovac Biotech signed an agreement with a drug maker in Brazil to conduct the final phase of the three part human testing of its CoronaVac vaccine, a Bloomberg report said.

Once approved by Brazilian authorities, Sinovac and Butantan will begin the trial involving 9,000 people in july. The Brazilian drug maker will get license for Chinese vaccine and make it available in the South American Countries, Sinovac said.

Meanwhile in initial findings, the Sinovac Biotech vaccine is found to be safe and capable for increasing immune response from human trials.

The CoronaVac vaccine hasn’t caused any side effects and more than 90 per cent of people are discharged within 14 days interval and produced neutralizing antibodies after two weeks of vaccination, Sinovac said in a press release.

Using a killed version of COVID-19, Sinovac vaccine is one of the five Chinese experimental firms that reached the crucial final stage of human testing before they are approved for public use.

?Oxford AstraZeneca Coronavirus Vaccine

The AZD1222 vaccine is jointly developed by British pharma giant AstraZeneca and Oxford University is presently undergoing phase 2 trials with 10,000 volunteers. The last stage trials of vaccine will be conducted in Brazil.

Testing of experimental COVID-19 AZD1222 vaccine in healthy volunters started in Britain in the month of April 2020 with 1,000 people aged between 18 to 55.

Meanwhile, AstraZeneca got a deal with Europe Inclusive Vaccines Alliance to supply upto 400 million doses. For speed up production of vaccine by the end of 2020, alliance are forged by Germany, France, Italy and Netherlands.

AstraZeneca gives a statement that they have started mass production of their experimental vaccine and planned to roll out upto 2 billion doses in September 2020.

?Bharat Biotech COVID-19 Vaccine

India is making significant progress in producing indigenous coronavirus COVID-19 vaccineCovaxin. Indian Council of Medical Research (ICMR) has shot off letters to hospitals and medical institutions across India to expedite the clinical test approvals for Covaxin. ICMR is developing Covaxin together with Hyderabad based Bharat Biotech and therefore the National Institute of Virology (NIV). So far, 12 clinical sites have identified and therefore the clinical test process is probably going to start on July 7. The clinical test of BBV152 COVID vaccine has been termed as “Top priority projects which is being monitored at the top-most level of the government”. Results of the clinical trials are likely to be launched by Assumption , as per ANI report.

Johnson & Johnson COVID-19 vaccine

American firm Johnson & Johnson said that they accelerate the progress of human clinical trials for their recombinant Ad26.COV2-S vaccine by two months to the second half of July 2020. This decision may allow Johnson & Johnson to take part in immense clinical trials program, Operation Warp Speed, planned by the US Government.

In March 2020, Johnson & Johnson signed a deal with the US Government for enough manufacturing capacity to produce more than 1 billion dosage.

Originally posted on June 16, 2020 @ 9:41 AM

Leave a Reply

Your email address will not be published. Required fields are marked *